Marché de la sarcoïdose cardiaque au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché de la sarcoïdose cardiaque au Moyen-Orient et en Afrique

La sarcoïdose est une maladie inflammatoire multisystémique dont l'étiologie est inconnue. La sarcoïdose cardiaque est diagnostiquée chez environ 2 à 5 % des patients atteints d'une autre sarcoïdose systémique. Cependant, l'autopsie a révélé que la sarcoïdose cardiaque peut atteindre 20 à 30 % aux États-Unis. La prévalence de la sarcoïdose est 3,8 fois supérieure chez les Afro-Américains que chez les Caucasiens aux États-Unis, au Moyen-Orient et en Afrique. La prévalence de la sarcoïdose cardiaque chez les patients japonais peut atteindre 58 %, et elle est la cause du décès chez 85 % des patients atteints de sarcoïdose au Japon. La sarcoïdose cardiovasculaire a un mauvais pronostic et l'état des patients peut se détériorer rapidement.

Français Data Bridge Market Research analyse que le marché de la sarcoïdose cardiaque, qui était de 228,90 millions USD en 2022, devrait atteindre 505,12 millions USD d'ici 2030, à un TCAC de 10,4 % au cours de la période de prévision 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché de la sarcoïdose cardiaque au Moyen-Orient et en Afrique      

Market Definition

Cardiac sarcoidosis is a rare inflammatory condition in which immune cells form granulomas in various areas of the heart, causing problems ranging from arrhythmia to heart failure. The causes of cardiac sarcoidosis are unknown at this time. An immune system overreaction may cause the disease to an infectious agent (such as bacteria or viruses), chemical, or allergen.

Middle East and Africa Cardiac Sarcoidosis Market Dynamics

Drivers

• Rise in cardiovascular disease

There is also an increase in the prevalence of obesity among adults and youth, which is one of the leading causes of cardiovascular disease, boosting market growth. As the prevalence of cardiovascular diseases rises, so does public awareness of health, prompting people to seek out simpler and more accessible diagnostics and treatment methods, such as easy-to-use cardiac monitoring devices. As a result, the market is expected to grow rapidly due to an increase in cardiovascular diseases during the forecast period.

• Enhanced demand of cardiac sarcoidosis drugs and diagnosis

Corticosteroid treatment may slow the progression of cardiac disease and improve survival, but it does not appear to reduce the frequency of ventricular arrhythmias. 16 Steroids' mechanism of action in cardiac sarcoidosis is unknown, but it is thought that these agents can slow the progression of inflammation and fibrosis by re-establishing a normal TH1/TH2 balance. w32 Prednisone doses of 60-80 mg per day are commonly prescribed at first. In one study, a 30 mg/day starting dose was found to be adequate for improving prognosis. These are the certain factors for the enhancement of cardiac sarcoidosis diagnosis.

Opportunities

• Develop new and advanced cardiac sarcoidosis drugs

Gallium67 scintigraphy Gallium67 scintigraphy is also used to diagnose myocardial involvement in sarcoidosis. Gallium67 accumulates only in areas of active inflammation, so the test is only positive when the disease is active. Okayama and colleagues reported that when thallium showed myocardial defects, gallium heart uptake did not add more diagnostic information but was predictive of the efficacy of corticosteroid treatment.

Gallium single photon emission computed tomography (SPECT) scanning is frequently difficult to visualise abnormal nuclide uptake into the myocardium, because of the inability to distinguish gallium uptake in other organs from that in the myocardium. Nakazawa and colleagues recently reported that dual SPECT using gallium67 and technetium99m can significantly improve the accuracy and spatial resolution of gallium67 SPECT scanning in the diagnosis of cardiac sarcoidosis.

Restraints/Challenges

• Antiarrhythmic treatment

Antiarrhythmic therapy and blockers are frequently required in the treatment of sarcoid heart disease. There have been no prospective studies evaluating the use of these agents in cardiac sarcoidosis patients. Blockers may increase the risk of heart block, and amiodarone may worsen restrictive lung disease in sarcoidosis. As a result, the doctor must carefully weigh the benefits and risks of prescribing these medications.

This cardiac sarcoidosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cardiac sarcoidosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In April 2020, Mallinckrodt sponsored an awareness programme launched by the American Lung Association (ALA) and the Foundation for Sarcoidosis Research (FSR) to empower sarcoidosis patients to fight against such a chronic disease and follow some measures to protect themselves from cardiac sarcoidosis. The launch of this awareness campaign aided the company in raising its public profile.
• In July 2019, Hikma Pharmaceuticals PLC and Civica entered into a five-year agreement to reduce the generic drug shortage in the United States. Most drugs used to treat cardiac sarcoidosis, including methotrexate, are available as generic drugs. This agreement enabled the company to maintain a continuous drug supply, allowing it to invest significantly in expanding its manufacturing capabilities.

Middle East and Africa Cardiac Sarcoidosis Market Scope

The cardiac sarcoidosis market is segmented on the basis of treatment, drugs type, inhibitors, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Diagnosis
• CT Scan
• PET
• ECG
• Others
• Drugs
• Methotrexate
• Corticosteroids
• Immunosuppressant Drugs
• Mycophenolate Mofetil
• Azathioprine
• Leflunomide
• Cyclophosphamide
• Others
• Antiarrhythmic Drugs
• Antimalarial Drugs
• Chloroquine
• Hydroxychloroquine
• Tumor Necrosis Factor-Alpha (Tnf-Alpha)

Inhibitors

• Adalimumab
• Infliximab
• Others

 Drugs Type

• Branded and Generic
• H.P. Acthar Gel
• Adempas
• Rayos
• Ofev
• Ara 290
• Others

Route of Administration

• Oral and Parenteral
• Intravenous
• Subcutaneous
• Others

 End User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Cardiac Sarcoidosis Market Regional Analysis/Insights

The cardiac sarcoidosis market is analyzed and market size insights and trends are provided by country, treatment, drugs type, inhibitors, route of administration, end user and distribution channel as referenced above.

The countries covered in the cardiac sarcoidosis market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Saudi Arabia dominates the Middle East and Africa cardiac sarcoidosis market because several market participants identified the country as an important manufacturing facility with numerous advantages.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The cardiac sarcoidosis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cardiac sarcoidosis market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cardiac sarcoidosis market. The data is available for historic period 2011-2021.

Competitive Landscape and Cardiac Sarcoidosis Market Share Analysis

The cardiac sarcoidosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cardiac sarcoidosis market.

Some of the major players operating in the cardiac sarcoidosis market are:

• Hikma Pharmaceuticals PLC (U.K.)
• Mylan N.V. (U.S.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Mallinckrodt (U.K.)
• AbbVie Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Relief Therapeutics (Switzerland)
• Sandoz International GmbH (Switzerland)
• Teva Pharmaceuticals USA, INC. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• sanofi-aventis U.S. LLC (U.S.)
• Zydus Pharmaceuticals, Inc. (U.S.)
• Fresenius Kabi USA (U.S.)
• Merck & Co., Inc. (U.S.)

SKU-54436